Evolving knowledge and therapy of inflammatory bowel disease.
about
Innate immunity in inflammatory bowel disease: a disease hypothesisTocilizumabAntibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potentialEnhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosaPeptidoglycan recognition proteins protect mice from experimental colitis by promoting normal gut flora and preventing induction of interferon-gammaTherapeutic potential of Yersinia anti-inflammatory components.Enhanced transduction of colonic cell lines in vitro and the inflamed colon in mice by viral vectors, derived from adeno-associated virus serotype 2, using virus-microbead conjugates bearing lectin.Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycleRole of CCL25/CCR9 in immune homeostasis and disease.Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean feverPredicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.Chemistry meets biology in colitis-associated carcinogenesisTargeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis.Acquisition of antigen-presenting functions by neutrophils isolated from mice with chronic colitis.Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritisEnhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis.The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease.Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases.Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006.Polymeric nano- and microparticle technologies for oral gene delivery.IBD serological panels: facts and perspectives.Aberrant activation of nuclear factor of activated T cell 2 in lamina propria mononuclear cells in ulcerative colitis.Prebiotics in chronic intestinal inflammation.Persistent retention of colitogenic CD4+ memory T cells causes inflammatory bowel diseases to become intractable.A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora.Investigational therapies for celiac disease.Importance of disrupted intestinal barrier in inflammatory bowel diseases.Immunomodulators for all patients with inflammatory bowel disease?Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Insights into inflammatory bowel disease using Toxoplasma gondii as an infectious trigger.Biological therapies for inflammatory bowel disease: controversies and future options.Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence.Myeloid-derived suppressor cells in the inflammatory bowel diseases.Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: impact on microRNAs expression and microbiota composition.Tumor necrosis factor suppresses NR5A2 activity and intestinal glucocorticoid synthesis to sustain chronic colitis.Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.Targeting methionine cycle as a potential therapeutic strategy for immune disorders.Infliximab in ulcerative colitis.Butyrate mediates nucleotide-binding and oligomerisation domain (NOD) 2-dependent mucosal immune responses against peptidoglycan.
P2860
Q22252859-5A6B4A52-81B4-4322-9F87-2EB802D63B9CQ24655317-10DCF0CF-4D9F-409F-9175-072E70AC2CE3Q27676429-85C91163-14DC-4889-95C8-0FE0B9B7741EQ28476816-6F565F44-A336-4D01-A32F-819C6BE8D1AEQ28587904-EAC5212B-6B02-4A31-8DD4-D9BA5A60E2BFQ33304192-BB064A71-B2B4-4859-B807-999201AABF6CQ33307618-16C465FC-7457-490D-835C-7089247DB900Q33350222-0E830307-5294-4506-9142-E4F3018CA907Q33579416-E831014F-D8F7-4E11-BBC2-3C10487940DBQ33742607-C6F9D0B1-EE69-432F-A486-9B8582E577A4Q33844419-271F2392-8ECE-4009-8EA2-5563056A0BE9Q34637606-E3C9BB70-5C75-4CCA-B8AA-09CCA5339E68Q35047726-D9834894-8840-4B50-866C-179881A6E65AQ35136750-547C3406-1B78-4DEA-8633-8E6686A14D29Q35685541-36752DDA-6DE8-40DA-A42B-F1EBD8CA403AQ35769069-B391E622-0978-4F47-A9FB-CD576FDBBC8AQ36052635-42E07FED-2584-45A6-AAB6-CD04D8C19564Q36446929-8C8A1F6B-2711-4BAA-8F1C-5A598A0D2442Q36502842-30C69D40-2232-4ED0-967E-3A843ABA280CQ36739682-7B4ADA8F-184A-445D-BA8F-480ED28A220DQ36815912-FB5678EB-1966-4C09-8877-75E5570C68D7Q36884782-E9F95E5C-376E-49EE-B5D3-BCB25D80B368Q37226310-32AB1563-7C9B-4D76-B786-6CD68DE6052EQ37285115-171E4C99-0D0E-47A4-B58D-0076DB6E45B4Q37325656-DB757DE2-64D7-4C57-9CBF-9AA9AF049169Q37363427-979EAFA4-C8E9-4E3E-8AD4-68CB342055E8Q37638684-16AED050-C760-4B10-82D2-E0183FD2786EQ37781315-5C3D7FB2-B301-49FF-954A-1A80D9204B04Q37823320-26E11329-FA6D-4D62-9846-6CE91AFB85DBQ37847059-9BFB2CE3-8F33-4D22-B3D2-54CC1CDF26F0Q37953824-4A722161-7A48-4887-BF03-FE18BC3DBEA3Q37960183-E95B1FD5-7FB4-4064-A83D-EE93F3C76312Q37996392-8195242B-D126-458F-A10C-F5ACEBFFAFF7Q38118052-57C5741D-C8C1-4AB0-9322-4F977FB88D27Q38650504-7640E7A7-B358-41DE-9E1A-78E8F251F239Q39020790-74488364-7CD6-4517-AFDB-A3981966F7B5Q39249504-77F8D905-D845-4A64-82F5-72B2AF2C9837Q40075590-2152763A-8D0D-41FB-9147-D01BA7BEE521Q41860347-63F0FCC1-5F6A-4B9D-AB48-08EDD474019EQ43261028-E4DCB944-3B95-48BB-82A6-F60E712D3A59
P2860
Evolving knowledge and therapy of inflammatory bowel disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Evolving knowledge and therapy of inflammatory bowel disease.
@ast
Evolving knowledge and therapy of inflammatory bowel disease.
@en
type
label
Evolving knowledge and therapy of inflammatory bowel disease.
@ast
Evolving knowledge and therapy of inflammatory bowel disease.
@en
prefLabel
Evolving knowledge and therapy of inflammatory bowel disease.
@ast
Evolving knowledge and therapy of inflammatory bowel disease.
@en
P2860
P356
P1476
Evolving knowledge and therapy of inflammatory bowel disease.
@en
P2093
Daniel K Podolsky
Joshua R Korzenik
P2860
P2888
P304
P356
10.1038/NRD1986
P577
2006-03-01T00:00:00Z